- Research works
- 101 ▼ 20% vs 2013–17
- Citations
- 2k 19.7 per fractional work
- Top-10% rate
- 23.2% record average 16.5%
- Open access
- 27% world 28%
Not ranked overall: Affimed Therapeutics (Germany) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 33.4×. Every wedge is a field page.
- Immunology and Microbiology 33.4×
- Medicine 2.8×
- Biochemistry, Genetics and Molecular Biology 1.6×
- Pharmacology, Toxicology and Pharmaceutics 1.3×
- Neuroscience 1.0×
- Materials Science 0.4×
- Mathematics 0.2×
- Health Professions 0.1×
- Economics, Econometrics and Finance 0.1×
- Business, Management and Accounting 0.1×
- Engineering 0.0×
Who are the top researchers at Affimed Therapeutics (Germany)?
Ranked on the composite score, Martin Treder and Uwe Reusch lead among researchers whose main affiliation is Affimed Therapeutics (Germany).
- 1 Martin Treder Germany · #1,547,150 worldwide 3 citations · 24 works
- 2 Uwe Reusch Germany · #1,548,346 worldwide 16 citations · 17 works
Which keywords describe research at Affimed Therapeutics (Germany)?
By fractional works in all years, weighted toward what it does more of than the world: Glycosylation, Monoclonal Antibodies, Therapeutic Antibodies, Antibody Engineering, Fc Receptors, Cancer Immunotherapy, Lymphoma and Immunotherapy.
- Protein Aggregation
- Immune Regulation
- Immune Checkpoint Blockade
- Immunogenicity
- Prognostic Factors
- Biopharmaceuticals
- Angiogenesis
- Classification
- Autoimmunity
- Immunity
- Rituximab
- Mucins
- Immune System
- NK Cell Recognition
- Leukemia
- CAR T Cells
- Immunotherapy
- Cancer Immunotherapy
- Antibody Engineering
- Monoclonal Antibodies
- Glycosylation
- Therapeutic Antibodies
- Fc Receptors
- Lymphoma
- Tumor Regression
- Chimeric Antigen Receptor
- Cancer
- Natural Killer Cells
- Glycans
- PET Imaging
- Innate Immunity
- Antigen Presentation
- Dendritic Cells
- Molecular Profiling
- Tumor Microenvironment
- Monoclonal Antibody
- Foxp3
- TGF-ß
- PD-1 and PD-L1
- Recombinant Proteins
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Glycosylation32▲ 146×3 topics
- Monoclonal Antibodies27▲ 187×3 topics
- Therapeutic Antibodies26▲ 200×2 topics
- Antibody Engineering24▲ 243×1 topic
- Fc Receptors24▲ 243×1 topic
- Cancer Immunotherapy23▲ 166×3 topics
- Lymphoma22▲ 149×3 topics
- Immunotherapy20▲ 30×5 topics
- Tumor Regression20▲ 223×2 topics
- CAR T Cells18▲ 423×1 topic
- Chimeric Antigen Receptor18▲ 423×1 topic
- Leukemia18▲ 281×2 topics
- Cancer10▲ 6.9×5 topics
- NK Cell Recognition8▲ 82×1 topic
- Natural Killer Cells8▲ 82×1 topic
- Immune System7▲ 21×2 topics
- Glycans7▲ 81×1 topic
- Mucins7▲ 81×1 topic
- PET Imaging6▲ 27×3 topics
- Rituximab5▲ 31×2 topics
- Innate Immunity4▲ 12×3 topics
- Immunity4▲ 12×2 topics
- Antigen Presentation4▲ 37×1 topic
- Autoimmunity4▲ 18×2 topics
- Dendritic Cells4▲ 33×1 topic
- Classification4▲ 10×1 topic
- Molecular Profiling4▲ 31×1 topic
- Angiogenesis4▲ 8.4×5 topics
- Tumor Microenvironment4▲ 9.9×5 topics
- Biopharmaceuticals3▲ 50×3 topics
- Monoclonal Antibody3▲ 49×2 topics
- Prognostic Factors3▲ 6.1×5 topics
- Foxp33▲ 35×1 topic
- Immunogenicity3▲ 49×2 topics
- TGF-ß3▲ 15×1 topic
- Immune Checkpoint Blockade2▲ 43×1 topic
- PD-1 and PD-L12▲ 43×1 topic
- Immune Regulation2▲ 17×2 topics
- Recombinant Proteins2▲ 43×2 topics
- Protein Aggregation2▲ 26×2 topics
Which research topics does Affimed Therapeutics (Germany) publish most on?
By volume in 2022–2025: CAR-T cell therapy research, Immune Cell Function and Interaction, Monoclonal and Polyclonal Antibodies Research and T-cell and B-cell Immunology.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 CAR-T cell therapy research Oncology 4 works
- 2 Immune Cell Function and Interaction Immunology 3 works
- 3 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 2 works
- 4 T-cell and B-cell Immunology Immunology 1 works
- 5 Immunotherapy and Immune Responses Immunology 1 works
- 6 Cancer Immunotherapy and Biomarkers Oncology 1 works
- 7 Lymphoma Diagnosis and Treatment Pathology and Forensic Medicine 0 works
- 8 Glycosylation and Glycoproteins Research Molecular Biology 0 works
- 9 HER2/EGFR in Cancer Research Oncology 0 works
- 10 Phagocytosis and Immune Regulation Immunology 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Affimed Therapeutics (Germany)'s research output changed?
Output in 2018–2022 was 20% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Heidelberg
- Heidelberg University
- University Hospital Heidelberg
- German Cancer Research Center
- Max Planck Institute for Nuclear Physics
- Chirurgische Universitätsklinik Heidelberg
- DKFZ-ZMBH Alliance
- Max Planck Institute for Astronomy
- Hautklinik Heidelberg
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.